(2R,3R,7R,8R)-5,5-dimethyl-4,6,18-trioxa-1,10,11,12-tetrazapentacyclo[8.6.1.12,8.03,7.013,17]octadeca-11,13(17),14-trien-16-one | 866826-65-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2R,3R,7R,8R)-5,5-dimethyl-4,6,18-trioxa-1,10,11,12-tetrazapentacyclo[8.6.1.12,8.03,7.013,17]octadeca-11,13(17),14-trien-16-one
• CAS: 866826-65-5
• 化学式: C₁₃H₁₄N₄O₄
• 分子量: 290.279
• InChiKey: MYVHYDMSYPLDPA-UGKPPGOTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  78.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2R,3R,7R,8R)-5,5-dimethyl-4,6,18-trioxa-1,10,11,12-tetrazapentacyclo[8.6.1.12,8.03,7.013,17]octadeca-11,13(17),14-trien-16-one 在 盐酸 、 溴 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 12.0h， 生成 6,9-Epoxy-5H,6H-1,2,5a,10a-tetraazacyclooct[cd]inden-5-one, 4-bromo-7,8,9,10-tetrahydro-7,8-dihydroxy-, (6R,7R,8S,9R)-
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel Anti-hepatitis C Agents: N³,5‘-Cyclo-4-(β-d-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one Derivatives

  摘要：

  Several 6- and 7-monosubstituted N-3 5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin5-one derivatives as well as the 5-thiono analogue were synthesized, providing structure-anti-hepatitis C virus (HCV) activity relationships for the series. Among the compounds synthesized, the 6-bromo, 7-methylamino, and 5-thiono analogues exhibited more potent anti-HCV activity in an HCV subgenomic replicon cell based assay (EC90 = 1.9, 7.4, and 10.0 mu M, respectively) than the lead compound N-3, 5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo [4,5-b] pyridin-5-one (EC90 = 79.8 mu M).

  DOI：

  10.1021/jm058223t
• 作为产物：
  描述：

  5-硝基-1-beta-D-呋喃核糖基-2(1H)-吡啶酮 在 sodium azide 、 对甲苯磺酸 、 三苯基膦 、 丙酮 、 偶氮二甲酸二乙酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 (2R,3R,7R,8R)-5,5-dimethyl-4,6,18-trioxa-1,10,11,12-tetrazapentacyclo[8.6.1.12,8.03,7.013,17]octadeca-11,13(17),14-trien-16-one
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel Anti-hepatitis C Agents: N³,5‘-Cyclo-4-(β-d-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one Derivatives

  摘要：

  Several 6- and 7-monosubstituted N-3 5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin5-one derivatives as well as the 5-thiono analogue were synthesized, providing structure-anti-hepatitis C virus (HCV) activity relationships for the series. Among the compounds synthesized, the 6-bromo, 7-methylamino, and 5-thiono analogues exhibited more potent anti-HCV activity in an HCV subgenomic replicon cell based assay (EC90 = 1.9, 7.4, and 10.0 mu M, respectively) than the lead compound N-3, 5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo [4,5-b] pyridin-5-one (EC90 = 79.8 mu M).

  DOI：

  10.1021/jm058223t

文献信息

• Synthesis and Structure−Activity Relationships of Novel Anti-hepatitis C Agents: <i>N</i>³,5‘-Cyclo-4-(β-<scp>d</scp>-ribofuranosyl)-<i>vic</i>-triazolo[4,5-<i>b</i>]pyridin-5-one Derivatives
  作者：Peiyuan Wang、Jinfa Du、Suguna Rachakonda、Byoung-Kwon Chun、Phillip M. Tharnish、Lieven J. Stuyver、Michael J. Otto、Raymond F. Schinazi、Kyoichi A. Watanabe

  DOI：10.1021/jm058223t

  日期：2005.10.1

  Several 6- and 7-monosubstituted N-3 5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin5-one derivatives as well as the 5-thiono analogue were synthesized, providing structure-anti-hepatitis C virus (HCV) activity relationships for the series. Among the compounds synthesized, the 6-bromo, 7-methylamino, and 5-thiono analogues exhibited more potent anti-HCV activity in an HCV subgenomic replicon cell based assay (EC90 = 1.9, 7.4, and 10.0 mu M, respectively) than the lead compound N-3, 5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo [4,5-b] pyridin-5-one (EC90 = 79.8 mu M).